Fact CheckerSign in

NCT04300270Active, not recruiting

Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment

Validation of a Novel Smartphone-based Photoplethysmographic Method for Ambulatory Heart Rhythm Monitoring in Connection to Treatment of Atrial Fibrillation With Direct Current Cardioversion

Source: ClinicalTrials.gov · Last updated 5 Mar 2025

Brief summary (registry, in English)

Atrial fibrillation is a heart rhythm disorder with increased risk of stroke, heart failure, dementia and death. The severity of symptoms in atrial fibrillation varies markedly, ranging from no symptoms to those with disabling symptoms. An ECG recording is currently mandatory for diagnosing atrial fibrillation. A portable method for heart rhythm diagnostics that is readily available is currently missing in clinical practice. If a standard smartphone could be used for heart rhythm diagnostics, the availability could improve greatly. Treatment with direct current cardioversion is a procedure in which the heart rhythm is normalized by an electrical shock through the chest. Patients with atrial fibrillation are in some cases recommended treatment with direct current cardioversion but the procedure is costly, has a high recurrence rate and includes an increased risk for stroke. In this study we will validate the use of a novel smartphone-based method for heart rhythm diagnostics when used by patients in their home environment. The novel method is using the smartphone camera as a sensor. Patients will be doing heart rhythm measurements with the novel smartphone-based method in their home environment for 30 days after successfully receiving treatment of atrial fibrillation with direct current cardioversion. The novel smartphone-based method will be validated against simultaneous recordings with mobile ECG. We will also study the feasibility in using smartphone recordings and mobile ECG in the home environment the weeks before receiving treatment with direct current cardioversion, to study the possible benefit of detecting spontaneous conversions to normal heart rhythm and missed doses of treatment with blood thinning medication, both of which will lead to cancellation or detention of the cardioversion procedure.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
480 (estimated)
First submitted
4 Mar 2020
Start date
27 Nov 2018
Primary completion date
1 Apr 2025
Lead sponsor
Karolinska Institutet
NCT number
NCT04300270

What you commit to

  • Study type: Observational
  • Planned participants: 480
  • From 27 Nov 2018 to the primary completion date, 1 Apr 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with a spontaneous return to sinus rhythm diagnosed at a screening visit 2 to 4 weeks prior to the scheduled treatment with direct current cardioversion.

Other illness

  • Patients with implantable cardiac devices.
    • Clinical implementation cohort:
  • Patients with implantable cardiac devices.

Who the study is looking for

  • Patients undergoing direct current cardioversion successfully for treatment of atrial fibrillation or atrial flutter and have a normal heart rhythm after the treatment.
  • Patients planned for direct current cardioversion for treatment of atrial fibrillation or atrial flutter.

Criteria the registry did not label

  • Validation cohort:

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Danderyd University Hospital
Coordinator of this site? Confirm its status
StockholmSwedenUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.